Nine Chapters Capital Management’s Harvard Bioscience HBIO Stock Holding History

Nine Chapters Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,780	Closed	-$162K	–	1035
2015 Q1	$162K	Buy	2,780 +280	+11%	+$15K	0.01%	861
2014 Q4	$142K	Buy	2,500 +510	+26%	+$24.3K	0.01%	845
2014 Q3	$81K	Sell	1,990 -1,000	-33%	-$46K	0.01%	941
2014 Q2	$136K	Buy	+2,990	New	+$126K	0.01%	858

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Nine Chapters Capital Management's HBIO Position: Q2 2015 in Review

Nine Chapters Capital Management sold out of Harvard Bioscience (HBIO) in Q2 2015, closing a stake of 2,780 shares — an estimated $162K sold.

Nine Chapters Capital Management first reported a position in HBIO in Q2 2014 and held it in 4 quarters. The position peaked at $162K in Q1 2015. 84 funds tracked by Wall St. Rank hold HBIO as of Q2 2015.

Nine Chapters Capital Management reported no remaining Harvard Bioscience position as of Q2 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 2,780 Harvard Bioscience shares in Q2 2015, an estimated $162K.
Nine Chapters Capital Management first reported a position in Harvard Bioscience in Q2 2014 and held it in 4 quarters.
Nine Chapters Capital Management's Harvard Bioscience position peaked at $162K in Q1 2015.
84 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2015.

Based on Nine Chapters Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.